An engineered monomer binding-protein for alpha-syn efficiently inhibits the proliferation of amyloid fibrils

 

Agerschou, E., Flagmeier, P., Saridaki, T., et al.

eLife 2019, vol:8, e46112 doi: 10.7554/eLife.46112

Abstract

Removing or preventing the formation of α-synuclein aggregates is a plausible strategy against Parkinson’s disease. To this end, we have engineered the β-wrapin AS69 to bind monomeric α-synuclein with high affinity. In cultured cells, AS69 reduced the self-interaction of α-synuclein and formation of visible α-synuclein aggregates. In flies, AS69 reduced α-synuclein aggregates and the locomotor deficit resulting from α-synuclein expression in neuronal cells. In biophysical experiments in vitro, AS69 highly sub-stoichiometrically inhibited both primary and autocatalytic secondary nucleation processes, even in the presence of a large excess of monomer. We present evidence that the AS69-α-synuclein complex, rather than the free AS69, is the inhibitory species responsible for sub-stoichiometric inhibition of secondary nucleation. These results represent a new paradigm that high affinity monomer binders can lead to strongly sub-stoichiometric inhibition of nucleation processes.

View Publication

Topics: Neurodegenerative diseases, Monolith – MicroScale Thermophoresis, MST,  Publications

 

 

Previous Article
Rescue of cognitive deficits in APP/PS1 mice by accelerating the aggregation of ß-amyloid peptide
Rescue of cognitive deficits in APP/PS1 mice by accelerating the aggregation of ß-amyloid peptide

Up next
Quantitative thermophoretic study of disease-related protein aggregates
Quantitative thermophoretic study of disease-related protein aggregates

Characterize the molecular mechanisms of neurodegenerative diseases

Learn how